In Brief
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for September 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.”